OncoSec Medical Inc EV / EBITDA
Cos'è EV / EBITDA di OncoSec Medical Inc?
EV / EBITDA di OncoSec Medical Inc è N/A
Qual è la definizione di EV / EBITDA?
EV / EBITDA è il valore aziendale diviso per guadagni prima di interessi, tasse, deprezzamento e ammortamento. È una misura di quanto sia costosa una azione ed è più frequentemente valida per i confronti tra le aziende rispetto al rapporto prezzo / guadagno. Misura il prezzo (sotto forma di valore d'impresa) che un investitore paga a vantaggio del flusso di cassa della società (sotto forma di EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
Cosa fa OncoSec Medical Inc?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar